Verition Fund Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$773K Sell
6,119
-590
-9% -$77.7K ﹤0.01% 1516
2026
Q1
$935K Sell
6,709
-61,468
-90% -$8.61M 0.01% 1334
2025
Q4
$8.37M Sell
68,177
-667
-1% -$81.1K 0.03% 551
2025
Q3
$7.64M Buy
68,844
+44,757
+186% +$5.09M 0.03% 724
2025
Q2
$2.67M Sell
24,087
-272,388
-92% -$29M 0.01% 1707
2025
Q1
$33.2M Buy
296,475
+161,666
+120% +$16.7M 0.15% 98
2024
Q4
$12.5M Buy
134,809
+93,663
+228% +$8.43M 0.05% 425
2024
Q3
$3.45M Sell
41,146
-60,372
-59% -$4.61M 0.02% 1087
2024
Q2
$6.97M Buy
101,518
+34,101
+51% +$2.28M 0.04% 529
2024
Q1
$4.94M Buy
67,417
+20,225
+43% +$1.56M 0.03% 686
2023
Q4
$3.82M Buy
47,192
+9,062
+24% +$705K 0.03% 541
2023
Q3
$2.86M Buy
+38,130
New +$2.93M 0.03% 649
2023
Q1
Sell
-10,608
Closed -$911K 2300
2022
Q4
$911K Sell
10,608
-37,413
-78% -$2.96M 0.01% 956
2022
Q3
$2.96M Buy
48,021
+19,171
+66% +$1.21M 0.03% 682
2022
Q2
$1.78M Sell
28,850
-20,292
-41% -$1.26M 0.04% 728
2022
Q1
$2.92M Buy
49,142
+25,149
+105% +$1.61M 0.04% 707
2021
Q4
$1.74M Buy
+23,993
New +$1.65M 0.01% 969
2021
Q2
Sell
-122,516
Closed -$7.92M 1983
2021
Q1
$7.92M Buy
122,516
+115,611
+1,674% +$7.45M 0.09% 137
2020
Q4
$402K Buy
+6,905
New +$417K ﹤0.01% 728
2020
Q3
Sell
-48,277
Closed -$3.71M 1185
2020
Q2
$3.71M Buy
+48,277
New +$3.7M 0.12% 137
2020
Q1
Sell
-60,381
Closed -$4.17M 777
2019
Q4
$3.92M Buy
60,381
+17,399
+40% +$1.13M 0.07% 174
2019
Q3
$2.72M Sell
42,982
-29,664
-41% -$1.94M 0.08% 174
2019
Q2
$4.91M Buy
72,646
+25,597
+54% +$1.68M 0.14% 114
2019
Q1
$3.06M Sell
47,049
-26,902
-36% -$1.79M 0.12% 122
2018
Q4
$4.63M Buy
73,951
+4,244
+6% +$297K 0.33% 63
2018
Q3
$5.38M Buy
69,707
+33,504
+93% +$2.53M 0.19% 85
2018
Q2
$2.56M Buy
36,203
+27,846
+333% +$1.97M 0.16% 136
2018
Q1
$630K Sell
8,357
-15,835
-65% -$1.26M 0.05% 546
2017
Q4
$1.73M Buy
24,192
+16,548
+216% +$1.26M 0.16% 125
2017
Q3
$619K Buy
+7,644
New +$585K 0.05% 479
2017
Q1
Sell
-26,495
Closed -$1.9M 1280
2016
Q4
$1.9M Buy
+26,495
New +$1.97M 0.16% 120
2016
Q3
Sell
-5,112
Closed -$426K 1200
2016
Q2
$426K Buy
5,112
+291
+6% +$25.8K 0.05% 453
2016
Q1
$443K Sell
4,821
-4,441
-48% -$400K 0.07% 357
2015
Q4
$937K Buy
9,262
+6,066
+190% +$631K 0.18% 112
2015
Q3
$314K Buy
+3,196
New +$355K 0.08% 329
2014
Q4
Sell
-5,538
Closed -$590K 467
2014
Q3
$590K Buy
+5,538
New +$542K 0.08% 202
2014
Q2
Sell
-3,619
Closed -$256K 703
2014
Q1
$256K Buy
3,619
+521
+17% +$40.9K 0.04% 317
2013
Q4
$233K Sell
3,098
-9,988
-76% -$695K 0.04% 346
2013
Q3
$822K Buy
+13,086
New +$782K 0.12% 135

Other funds holding GILD

Verition Fund Management's GILD Position: Q2 2026 in Review

Verition Fund Management reduced its Gilead Sciences (GILD) stake by 8.8% in Q2 2026, selling an estimated $77.7K and leaving 6,119 shares worth $773K. The position accounts for ﹤0.01% of the portfolio, ranked #1516.

Verition Fund Management first reported a position in GILD in Q3 2013 and has held it in 39 quarters since. The position peaked at $33.2M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Verition Fund Management held 6,119 shares of Gilead Sciences worth $773K as of Q2 2026.
  • Verition Fund Management sold 590 Gilead Sciences shares in Q2 2026, an estimated $77.7K.
  • Gilead Sciences made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1516 holding.
  • Verition Fund Management first reported a position in Gilead Sciences in Q3 2013 and has held it in 39 quarters since.
  • Verition Fund Management's Gilead Sciences position peaked at $33.2M in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.